ESH 2017 | Combating AML

Andrew Wei

Andrew Wei, MBBS, PhD, FRACP, FRCPA from Alfred Hospital and Monash University, Melbourne, Australia discusses how a novel molecule, S64315, has the potential to combat acute myeloid leukaemia (AML). S64315 has started Phase I trials (NCT02979366) to assess how effective it is against the MCL-1 protein. Dr Wei also discusses the synergy of using venetoclax and other drugs targeting BCL-2 in combination with drugs targeting MCL-1 to treat AML, and how this could reduce the toxicity of the treatment. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).

Share this video